Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2026
0mins
Source: Newsfilter
- Cardiovascular Event Risk Reduction: In the VESALIUS-CV clinical trial, Repatha reduced the risk of first major adverse cardiovascular events by 31% in high-risk primary prevention patients, highlighting its critical role in cardiovascular disease prevention.
- Significant LDL-C Reduction: The Repatha treatment group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, indicating its substantial efficacy in cholesterol lowering, potentially offering better cardiovascular protection for patients.
- Strategic Importance of Early Intervention: The findings underscore the importance of early and more intensive LDL-C lowering strategies in high-risk patients without known atherosclerosis, which may effectively reduce risk before cardiovascular events occur.
- Broad Applicability: Since its approval in 2015, Repatha has been used in over 8 million patients globally, demonstrating its wide applicability and potential market opportunities in cardiovascular disease management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 331.570
Low
280.00
Averages
363.10
High
425.00
Current: 331.570
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen CFO Peter Griffith Retires, Thomas Dittrich to Rejoin
- Executive Retirement: Amgen announced the retirement of CFO Peter Griffith, who has served since 2020, effective January 2027, marking a significant leadership transition for the company.
- New Appointment: Thomas Dittrich will rejoin Amgen as executive vice president on July 1, 2026, and will assume the CFO role on September 1, 2026, bringing extensive financial management experience from his previous roles at Galderma and others.
- Transition Support: Griffith will remain with the company until January 2027 to facilitate a smooth leadership transition, ensuring stability during this critical period for Amgen.
- Industry Background: Dittrich's prior experience as CFO at Shire and Sulzer positions him well to enhance Amgen's financial strategy and operations moving forward, potentially driving improved efficiency and performance.
See More
Thomas Dittrich Returns to Amgen as CFO
- Executive Transition: Amgen announced that CFO Peter Griffith will retire on September 1, 2026, with Thomas Dittrich returning to take over on July 1, ensuring continuity in financial leadership for the company.
- Leadership Experience: Dittrich brings over 30 years of international leadership experience, having previously held senior finance roles at Amgen and most recently serving as CFO at Galderma, which is expected to provide Amgen with valuable industry insights and strategic direction.
- Transition Support: Griffith will remain with the company until January 2027 to facilitate a smooth leadership transition, ensuring stability and continuity in financial management during this critical period.
- Long-term Growth Strategy: During Griffith's tenure, he strengthened the company's financial foundation and supported disciplined capital allocation, laying a solid groundwork for Amgen's long-term growth strategy, which Dittrich's return is expected to further advance.
See More
AMGN Stock Rises 2.2% Amid Sector Gains
- Stock Performance: AMGN's stock is up approximately 2.2% by midday Tuesday, indicating strong performance within the biotechnology sector and reflecting market confidence in its future growth prospects.
- Industry Comparison: In comparison, Thermo Fisher Scientific Inc (TMO) is up about 1.5%, and Gilead Sciences Inc (GILD) is up about 1.8%, suggesting a positive trend in the biotechnology sector, with AMGN outperforming these competitors.
- Analyst Attention: AMGN is recognized as a 'top analyst pick' within the Dow, indicating positive expectations for its future performance, which may attract more investor interest.
- Market Sentiment: While the overall market sentiment is positive, the author's views do not necessarily reflect those of Nasdaq, urging investors to carefully assess market dynamics for informed decision-making.
See More
Eli Lilly's Stock Volatility and Future Outlook
- Stock Volatility Analysis: Eli Lilly's shares trended downward until late April, dropping below $900, but surged past $1,000 following the first-quarter earnings report, indicating strong market confidence in its future growth.
- Increased Competitive Pressure: While Eli Lilly dominates the anti-obesity market, competitors like Novo Nordisk are launching next-generation weight-loss drugs, which could pressure Eli Lilly's market share and pricing power in the coming years.
- R&D Investment Outlook: Strong sales growth in oncology, immunology, and neuroscience, bolstered by strategic acquisitions, is expected to drive Eli Lilly's stock price higher over the next few years, further solidifying its market leadership.
- AI Application Potential: Eli Lilly is exploring the use of artificial intelligence to enhance drug development, having built the industry's most powerful supercomputer, which could shorten drug discovery timelines by 1-2 years, significantly reducing R&D costs and boosting profit margins.
See More
Quantinuum's IPO Marks a Pivotal Moment in Quantum Computing
- Company Background: Quantinuum was formed in 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing, with major backing from Honeywell and blue-chip investors like Nvidia and JPMorgan, highlighting its strong support in the quantum computing sector.
- Technological Edge: Utilizing trapped-ion quantum computers, Quantinuum employs lasers to suspend individual atoms, yielding qubits with exceptionally high fidelity and long coherence times, and this full-stack approach enhances error correction compared to Rigetti Computing's superconducting qubits.
- Financial Performance: In 2025, Quantinuum generated $30.9 million in revenue, a 35% year-over-year increase, yet net losses widened to $192.6 million, reflecting substantial investments in R&D and marketing, indicating that commercialized quantum AI solutions are still in development.
- IPO Outlook: Market speculation suggests Quantinuum's IPO could value the company near $20 billion, double its $10 billion valuation from a September 2025 funding round, and despite its poor financial profile, the IPO could serve as a catalyst for the entire quantum ecosystem.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Amgen CFO Peter Griffith Retires, Thomas Dittrich to Rejoin
- Executive Retirement: Amgen announced the retirement of CFO Peter Griffith, who has served since 2020, effective January 2027, marking a significant leadership transition for the company.
- New Appointment: Thomas Dittrich will rejoin Amgen as executive vice president on July 1, 2026, and will assume the CFO role on September 1, 2026, bringing extensive financial management experience from his previous roles at Galderma and others.
- Transition Support: Griffith will remain with the company until January 2027 to facilitate a smooth leadership transition, ensuring stability during this critical period for Amgen.
- Industry Background: Dittrich's prior experience as CFO at Shire and Sulzer positions him well to enhance Amgen's financial strategy and operations moving forward, potentially driving improved efficiency and performance.
See More
Thomas Dittrich Returns to Amgen as CFO
- Executive Transition: Amgen announced that CFO Peter Griffith will retire on September 1, 2026, with Thomas Dittrich returning to take over on July 1, ensuring continuity in financial leadership for the company.
- Leadership Experience: Dittrich brings over 30 years of international leadership experience, having previously held senior finance roles at Amgen and most recently serving as CFO at Galderma, which is expected to provide Amgen with valuable industry insights and strategic direction.
- Transition Support: Griffith will remain with the company until January 2027 to facilitate a smooth leadership transition, ensuring stability and continuity in financial management during this critical period.
- Long-term Growth Strategy: During Griffith's tenure, he strengthened the company's financial foundation and supported disciplined capital allocation, laying a solid groundwork for Amgen's long-term growth strategy, which Dittrich's return is expected to further advance.
See More
AMGN Stock Rises 2.2% Amid Sector Gains
- Stock Performance: AMGN's stock is up approximately 2.2% by midday Tuesday, indicating strong performance within the biotechnology sector and reflecting market confidence in its future growth prospects.
- Industry Comparison: In comparison, Thermo Fisher Scientific Inc (TMO) is up about 1.5%, and Gilead Sciences Inc (GILD) is up about 1.8%, suggesting a positive trend in the biotechnology sector, with AMGN outperforming these competitors.
- Analyst Attention: AMGN is recognized as a 'top analyst pick' within the Dow, indicating positive expectations for its future performance, which may attract more investor interest.
- Market Sentiment: While the overall market sentiment is positive, the author's views do not necessarily reflect those of Nasdaq, urging investors to carefully assess market dynamics for informed decision-making.
See More
Eli Lilly's Stock Volatility and Future Outlook
- Stock Volatility Analysis: Eli Lilly's shares trended downward until late April, dropping below $900, but surged past $1,000 following the first-quarter earnings report, indicating strong market confidence in its future growth.
- Increased Competitive Pressure: While Eli Lilly dominates the anti-obesity market, competitors like Novo Nordisk are launching next-generation weight-loss drugs, which could pressure Eli Lilly's market share and pricing power in the coming years.
- R&D Investment Outlook: Strong sales growth in oncology, immunology, and neuroscience, bolstered by strategic acquisitions, is expected to drive Eli Lilly's stock price higher over the next few years, further solidifying its market leadership.
- AI Application Potential: Eli Lilly is exploring the use of artificial intelligence to enhance drug development, having built the industry's most powerful supercomputer, which could shorten drug discovery timelines by 1-2 years, significantly reducing R&D costs and boosting profit margins.
See More
Quantinuum's IPO Marks a Pivotal Moment in Quantum Computing
- Company Background: Quantinuum was formed in 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing, with major backing from Honeywell and blue-chip investors like Nvidia and JPMorgan, highlighting its strong support in the quantum computing sector.
- Technological Edge: Utilizing trapped-ion quantum computers, Quantinuum employs lasers to suspend individual atoms, yielding qubits with exceptionally high fidelity and long coherence times, and this full-stack approach enhances error correction compared to Rigetti Computing's superconducting qubits.
- Financial Performance: In 2025, Quantinuum generated $30.9 million in revenue, a 35% year-over-year increase, yet net losses widened to $192.6 million, reflecting substantial investments in R&D and marketing, indicating that commercialized quantum AI solutions are still in development.
- IPO Outlook: Market speculation suggests Quantinuum's IPO could value the company near $20 billion, double its $10 billion valuation from a September 2025 funding round, and despite its poor financial profile, the IPO could serve as a catalyst for the entire quantum ecosystem.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
